🇺🇸 nitrocamptothecin in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 7
Most-reported reactions
- Chronic Myelomonocytic Leukaemia — 1 report (14.29%)
- Gastric Perforation — 1 report (14.29%)
- Malignant Neoplasm Progression — 1 report (14.29%)
- Metastases To Abdominal Cavity — 1 report (14.29%)
- Metastases To Lung — 1 report (14.29%)
- Therapy Non-Responder — 1 report (14.29%)
- Trisomy 8 — 1 report (14.29%)
Other Other approved in United States
Frequently asked questions
Is nitrocamptothecin approved in United States?
nitrocamptothecin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for nitrocamptothecin in United States?
Alliance for Clinical Trials in Oncology is the originator. The local marketing authorisation holder may differ — check the official source linked above.